Drug Profile
BILR 355 BS
Alternative Names: BILR-355; BILR-355-BSLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antiretrovirals; Quinolines; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 28 Feb 2006 Phase-II clinical trials in HIV infections treatment in Germany (PO)
- 31 Jan 2006 Data presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2005) have been added to the Viral Infections antimicrobial activity section
- 10 Mar 2005 Data presented at the 12th Conference on Retroviruses and Opportunistic Infections (CROI-2005) have been added to the pharmacokinetics and Viral Infections antimicrobial activity sections